2021 Scientific Retreat- Session 3

Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment 
Thursday, October 28, 2021 | 9:40 AM – 12:00 PM PST 

Moderator: 
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia 

LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer 
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia 

Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC 
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre, Australia 

Targeting Micro-Metastatic Disease with Auger or Alpha Emitters 
Ana Kiess, MD, PhD, Johns Hopkins University 

The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy 
Cristina Müller, PhD, PD, Paul Scherrer Institute, Switzerland 

aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans 
Aseem Anand, PhD, Imaging-Oncology Biomarker, EXINI Diagnostics AB. Sweden (a wholly owned subsidiary of Lantheus Holdings) 

Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer? 
Andy Simmons, PhD, Clovis Oncology 

Insights & Future Predictions from 25 Years of PSMA Research 
Neil Bander, MD, Weill Cornell Medical College